[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354420-105":59,"doc-detail-354420-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","prevalence-and-determinants-of-female-sexual-dysfunction-and-its-association-with-neurotrophic-biomarkers-in-gynaecological-cancer-survivors-a-cross-sectional-study","Prevalence and Determinants of Female Sexual Dysfunction, and Its Association With Neurotrophic Biomarkers in Gynaecological Cancer Survivors - A Cross-Sectional Study","","Female sexual dysfunction in gynaecological cancer survivorship remains insufficiently addressed in clinical care. This cross-sectional observational study evaluated sexual dysfunction prevalence, identified risk factors, and examined correlations between sexual dysfunction and serum neurotrophic biomarkers. Among 200 sexually active survivors, sexual function was measured using the Hindi-validated Female Sexual Function Index (FSFI), while brain-derived neurotrophic factor, substance P, and neuropeptide Y were quantified by ELISA. FSD was highly prevalent and age emerged as the sole independent clinical predictor, with overall biomarker levels showing limited differences.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/prevalence-and-determinants-of-female-sexual-dysfunction-and-its-association-with-neurotrophic-biomarkers-in-gynaecological-cancer-survivors-a-cross-sectional-study/354420/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/prevalence-and-determinants-of-female-sexual-dysfunction-and-its-association-with-neurotrophic-biomarkers-in-gynaecological-cancer-survivors-a-cross-sectional-study/354420.png","ImageObject",300,407,{"name":92,"@type":93},"Blitz","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the main objective of the study?","Question",{"text":113,"@type":114},"To assess the prevalence of female sexual dysfunction in gynaecological cancer survivors, determine risk factors, and correlate sexual dysfunction with serum neurotrophic biomarkers.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was sexual dysfunction measured in the study?",{"text":118,"@type":114},"Sexual function was assessed using the Hindi-validated Female Sexual Function Index (FSFI), with FSFI \u003C 26.55 indicating dysfunction.",{"name":120,"@type":111,"acceptedAnswer":121},"Which factors were found to predict female sexual dysfunction independently?",{"text":122,"@type":114},"In multivariable analysis, age was the only independent clinical predictor of FSD (p = 0.02). Cancer site, stage, treatment modality, and menopausal status were not significant in this cohort.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},354420,1790396804,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":105,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},24464137899374,"https://us-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Prevalence and Determinants of Female Sexual Dysfunction, and Its Association With Neurotrophic Biomarkers in Gynaecological Cancer Survivors: A Cross-Sectional Study  \nCancer Control Volume 33: 1–11 © The Author(s) 2026 Article reuse guidelines:  \n[sagepub.com/journals-permissions](sagepub.com/journals-permissions)  \n[DOI: 10.1177/10732748261465284](DOI: 10.1177/10732748261465284)  \n[journals.sagepub.com/home/ccx](journals.sagepub.com/home/ccx)  \nNilanchali Singh1 , Shalini Singh2, Rizwana Quraishi2, DN Sharma3, Zakiya Zakiya1 , Seema Singhal1, Jyoti Meena1, Shivangi Mangal1, Garg Himakshi1, Rajesh Kumari1, Anju Singh1, and Neena Malhotra1  \nAbstract  \nIntroduction: Female sexual dysfunction (FSD) in any gynaecological cancer survivor is one aspect of female functioning that is neglected in survivorship care. Therefore, their actual prevalence is far from known to the treating physician. This study aimed to evaluate the prevalence of sexual dysfunction in gynaecological cancer survivors, determine its risk factors, and correlate sexual dysfunction with serum neurotropic factors. Methods: This was a cross-sectional, observational study among 200 gynaecological cancer survivors who are sexually active, conducted in the gynaecological cancer clinic at a tertiary care centre. Sexual function was assessed using the Hindi-validated Female Sexual Function Index (FSFI), and serum brain-derived neurotrophic factor (BDNF), substance P, and neuropeptide Y (NPY) were measured by ELISA. The correlation between these biomarkers, with domainsand subdomainsofthe female sexual function index, was explored. Results: In this cohort of 200 gynaecological cancer survivors, 189 (94.5%) women had FSD (FSFI \u003C26.55) . Age was the only independent clinical predictor of FSD in multivariable analysis (p = 0.02), while cancer site, stage, treatment modality, and menopausal status were not significant in this cohort. Overall biomarker levels did not differ between women with and without FSD. However, subdomain analysis showed high dysfunction rates in lubrication, orgasm, pain, and arousal, with significant biomarker differences for substance P and NPY in several dysfunctional subdomains. Conclusions: FSD was highly prevalent in gynaecological cancer survivors. While overall biomarker differences were not significant, subdomain-specific associations suggest that substance P and NPY may have a role in domain-level sexual dysfunction and merit further study.  \nKeywords  \nfemale sexual dysfunction, neurotrophic factors, gynaecological cancer survivors, female sexual function index, cervical cancer, ovarian cancer, endometrial cancer  \nReceived: 11 February 2026; Revised: 30 April 2026; Accepted: 17 June 2026  \n1Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi, India 2Department of Psychiatry, All India Institute of Medical Sciences, New Delhi, India  \n3Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India  \nCorresponding author:  \nNilanchali Singh, Obstetrics and Gynaecology, All India Institute of Medical Sciences, Room no. 708, 7th Floor, Mother & Child Block, Ansari Nagar, New Delhi 110029, India.  \nEmail: [nilanchalisingh@gmail.com](nilanchalisingh@gmail.com)  \nCreative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons  \nAttribution-NonCommercial 4.0 License ([https://creativecommons.org/licenses/by-nc/4.0/](https://creativecommons.org/licenses/by-nc/4.0/)) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages ([https://us.sagepub.com/en-us/nam/open-access-at-sage](https://us.sagepub.com/en-us/nam/open-access-at-sage)).  \n1. Introduction  \nGynaecological cancers represent a major global public health challenge. According to GLOBOCAN 2022, these cancers affected approximately 1.4 million wo","cbCaia6Cz1jh2nIF","https://ap.wps.com/l/cbCaia6Cz1jh2nIF","pdf",1932498,"English","# Abstract\n# Introduction\n# Methods\n# Results\n# Conclusions\n# Keywords","[{\"question\":\"What was the main objective of the study?\",\"answer\":\"To assess the prevalence of female sexual dysfunction in gynaecological cancer survivors, determine risk factors, and correlate sexual dysfunction with serum neurotrophic biomarkers.\"},{\"question\":\"How was sexual dysfunction measured in the study?\",\"answer\":\"Sexual function was assessed using the Hindi-validated Female Sexual Function Index (FSFI), with FSFI \\u003c 26.55 indicating dysfunction.\"},{\"question\":\"Which factors were found to predict female sexual dysfunction independently?\",\"answer\":\"In multivariable analysis, age was the only independent clinical predictor of FSD (p = 0.02). Cancer site, stage, treatment modality, and menopausal status were not significant in this cohort.\"}]","Prevalence and Determinants of Female Sexual Dysfunction, and Its Association With Neurotrophic Biomarkers in Gynaecological Cancer Survivors - A Cross-Sectional Study | PDF",1790110556,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/17516dbf7c46d54eb05092ef0b67a774.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/16f1f69229455338f82a1049edcd33bd.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a80bcf80107833d1b75acbb87e06531e.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0fad2bdbef47ee9648113f728310f351.webp",980,1306]